<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24004" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lactulose</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mukherjee</surname>
            <given-names>Samiran</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>John</surname>
            <given-names>Savio</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samiran Mukherjee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Savio John declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24004.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Lactulose is a versatile pharmaceutical agent helpful in preventing and treating clinical portal-systemic encephalopathy. By primarily targeting the reduction of intestinal production and absorption of ammonia, this drug addresses the root cause of the condition. Beyond its established efficacy in portal-systemic encephalopathy, lactulose has garnered recognition as a potential therapeutic solution for subacute clinical encephalopathy.</p>
        <p>Moreover, its application extends to managing chronic constipation, where the combined impact of its osmotic effect and modulation of intestinal motility contributes to its therapeutic effectiveness. This activity encompasses the pharmacological aspects of lactulose, detailing its mechanisms of action, potential adverse events, eligible patient populations, contraindications, and the essential role of the interprofessional team in the meticulous management of lactulose therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for lactulose therapy based on patient presentations and medical history.</p></list-item><list-item><p>Screen patients for contraindications or precautions to lactulose use, considering factors such as galactosemia, gastrointestinal obstruction, and electrolyte imbalances.</p></list-item><list-item><p>Apply knowledge of potential adverse events associated with lactulose, such as flatulence, abdominal discomfort, and electrolyte disturbances, and develop strategies to mitigate or manage them.</p></list-item><list-item><p>Develop&#x000a0;effective communication with patients about the benefits, risks, and proper use of lactulose, ensuring their understanding and adherence to the prescribed regimen.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24004&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24004">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24004.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Lactulose is used to prevent and treat clinical portal-systemic encephalopathy and was first used in clinical practice in 1966.<xref ref-type="bibr" rid="article-24004.r1">[1]</xref>&#x000a0;The drug's chief mechanism of action is to decrease the intestinal production and absorption of ammonia. Lactulose has also gained popularity as a potential therapeutic agent for managing subacute clinical encephalopathy.<xref ref-type="bibr" rid="article-24004.r2">[2]</xref> Lactulose is also a laxative for treating chronic constipation and has undergone study as early as the 1960s.<xref ref-type="bibr" rid="article-24004.r3">[3]</xref>&#x000a0;Lactulose's osmotic effect and its effect on intestinal motility receive credit for its therapeutic efficacy.<xref ref-type="bibr" rid="article-24004.r4">[4]</xref></p>
        <p>Lactulose can be helpful as a third-line agent for chronic constipation once lifestyle modifications and increasing fiber intake have failed.<xref ref-type="bibr" rid="article-24004.r4">[4]</xref> Because of lactulose's ability to significantly reduce intestinal transit time, it can also reduce deoxycholic acid's hypersaturation, thereby&#x000a0;inhibiting cholesterol stone formation.<xref ref-type="bibr" rid="article-24004.r5">[5]</xref> Recent studies have looked at lactulose for developing novel anticancer therapeutic agents due to its ability to bind to galectins (a carbohydrate-binding protein that plays a role in tumor progression).<xref ref-type="bibr" rid="article-24004.r6">[6]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lactulose powder for oral solution is indicated for the treatment of constipation. Lactulose therapy increases the number of days on which bowel movements occur and the total number of bowel movements in patients with a chronic history of constipation.</p>
          </list-item>
          <list-item>
            <p>Lactulose solution is indicated for preventing and treating portal-systemic encephalopathy, including&#x000a0;the stages of hepatic pre-coma and coma. In controlled studies, lactulose solution therapy decreases blood ammonia levels by 25% to 50%. In parallel, this may improve EEG patterns and the mental state of patients.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24004.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Lactulose, or 1,4-&#x003b2;-galactoside-fructose, is a non-absorbable synthetic disaccharide made of galactose and fructose.<xref ref-type="bibr" rid="article-24004.r7">[7]</xref>&#x000a0;The human small intestinal mucosa does not have the enzymes to split lactulose, so lactulose reaches the large bowel unchanged. Lactulose is metabolized in the colon by colonic bacteria to monosaccharides and then to volatile fatty acids, hydrogen, and methane. Lactulose reduces intestinal ammonia production and absorption in&#x000a0;3 ways.</p>
        <p>First, the colonic metabolism of sugars causes a laxative effect via increased intraluminal gas formation and osmolality, which reduces transit time and intraluminal pH. This laxative effect is also beneficial for constipation.<xref ref-type="bibr" rid="article-24004.r7">[7]</xref></p>
        <p>Next, lactulose promotes increased ammonia uptake by colonic bacteria, which utilize the trapped colonic ammonia as a nitrogen source for protein synthesis. The reduction of intestinal pH facilitates this process, which favors the conversion of ammonia (NH<sub>3</sub>) the gut bacteria produces to ammonium (NH<sub>4</sub><sup>+</sup>),&#x000a0;an ionized form of the molecule that cannot cross biological membranes.<xref ref-type="bibr" rid="article-24004.r8">[8]</xref><xref ref-type="bibr" rid="article-24004.r9">[9]</xref><xref ref-type="bibr" rid="article-24004.r10">[10]</xref></p>
        <p>Finally, lactulose also causes a reduction in intestinal production of ammonia. The acidic pH destroys urease-producing bacteria involved in the production of ammonia. The unabsorbed disaccharide also inhibits intestinal glutaminase activity, which blocks the intestinal uptake of glutamine and its metabolism to ammonia.</p>
        <p>Although a variety of mechanisms of action of lactulose that limit the production and absorption of ammonia in the gut, as explained above, have&#x000a0;been reported, other laxatives could probably have the same effects with better tolerability. Lactulose originally received FDA approval in the USA in 1977, but there are concerns regarding the adequacy of data to support the drug's efficacy. As lactulose is believed to be an effective therapy for hepatic encephalopathy, it cannot be ethically withheld from patients needing treatment. Thus, conducting human investigation review board-approved placebo-controlled trials in the US to confirm or refute the efficacy of lactulose remains difficult.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Lactulose is poorly absorbed when administered orally to man, and only small amounts reach the blood.&#x000a0;</p>
        <p><bold>Metabolism:</bold>&#x000a0;&#x000a0;Lactulose reaches the colon unchanged. In the colon, bacteria metabolize lactulose and form low molecular weight acids, which may lead to acidifying the colon contents.</p>
        <p><bold>Elimination:&#x000a0;</bold>Only 3% or less of lactulose is excreted in urine within 24 hours.</p>
      </sec>
      <sec id="article-24004.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Although the oral route (as a syrup) has been the standard mode of administration for the past several decades, it is also effective as a rectal enema.<xref ref-type="bibr" rid="article-24004.r1">[1]</xref><xref ref-type="bibr" rid="article-24004.r11">[11]</xref> Most of these studies were comparisons between lactulose/lactitol enemas and placebo. The few studies that have compared oral vs rectal lactulose have demonstrated inconclusive findings in the long term.<xref ref-type="bibr" rid="article-24004.r12">[12]</xref></p>
        <p>Lactitol, a second-generation disaccharide, is a crystalline powder unavailable in the United States.&#x000a0;Lactitol&#x000a0;is equally efficacious but better tolerated than&#x000a0;lactulose&#x000a0;and is usually prescribed at a dose of 10 to 90 g/d to cause&#x000a0;2 soft bowel movements per day. At present, the most commonly used regimens of lactulose are as follows.<xref ref-type="bibr" rid="article-24004.r13">[13]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Oral Route</bold>
</p>
        <p>For constipation, administration of 15&#x000a0;to 45 mL (or 10&#x000a0;to 30 g) 2&#x000a0;to 4 times daily until the formation of soft stools.</p>
        <p>In patients with hepatic encephalopathy, lactulose is typically given in syrup form at a dose of 15 to 30 mL&#x000a0;2 to&#x000a0;4 times a day to aim for&#x000a0;2 semisoft stools per day.</p>
        <p>For acute hepatic encephalopathy, a common option is to administer a bolus of 45 mL (30 g) and repeat the dose&#x000a0;hourly until the first bowel movement. Once the episode of encephalopathy has subsided, the dose can be titrated to achieve 2&#x000a0;or 3 soft bowel movements daily.</p>
        <p>
<bold>Rectal Route</bold>
</p>
        <p>This mode is preferred if there is any aspiration risk via the oral route. The preferred route is to administer 300 mL in 700 mL of water and have it retained in the colon for an hour, repeated every 2 hours until the episode resolves. The patient should be in the lateral recumbent position to optimize intestinal distribution.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>No specific dose adjustment information is available for lactulose in the manufacturer label for patients with hepatic impairment.</p>
        <p><bold>Renal impairment: </bold>No specific dose adjustment information is available for lactulose in the manufacturer label for patients with renal impairment.</p>
        <p><bold>Pregnancy considerations: </bold>Lactulose is a pregnancy category B drug. Based on reproduction studies conducted in mice, rats, and rabbits at 2 or 4 times the usual human oral dose, there has been no evidence of impaired fertility or fetal harm due to lactulose. However, there are no adequate and well-controlled studies conducted in pregnant women. Therefore, this drug should be used during pregnancy only if needed clearly.<xref ref-type="bibr" rid="article-24004.r14">[14]</xref><xref ref-type="bibr" rid="article-24004.r15">[15]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Whether lactulose is excreted in human milk is unknown. However, many drugs are excreted in human milk, so it would be advisable to exercise caution when lactulose is administered to a&#x000a0;breastfeeding&#x000a0;woman.</p>
        <p><bold>Pediatric patients: </bold>There is very little information available on the use of lactulose in pediatric patients. In adult studies, the main goal is to produce 2 to 3 soft stools daily. On that basis,&#x000a0;the recommended initial daily oral dose in infants would be 2.5 to 10 mL in divided doses. The daily dose of 0 to 90 mL is recommended for older children and adolescents. If this initial dose causes diarrhea, the dose should be lowered immediately. If diarrhea persists, lactulose treatment should be discontinued.<xref ref-type="bibr" rid="article-24004.r16">[16]</xref><xref ref-type="bibr" rid="article-24004.r17">[17]</xref></p>
        <p><bold>Older patients:</bold> No specific dose adjustment information is available for lactulose in the manufacturer label for&#x000a0;older patients.</p>
      </sec>
      <sec id="article-24004.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Because lactulose has insignificant absorption by the gut and undergoes rapid excretion by the kidneys, its effects remain localized to the gut microenvironment. Side effects would include increased bowel sounds (borborygmi), increased flatus, and a sensation of bloating. Since lactulose's intended use is to soften the stool quantity and increase the stool amount, its most significant side effect remains diarrhea. The diarrhea is dose-dependent and decreases in severity with a reduction in the dose of lactulose.<xref ref-type="bibr" rid="article-24004.r7">[7]</xref><xref ref-type="bibr" rid="article-24004.r18">[18]</xref></p>
      </sec>
      <sec id="article-24004.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications&#x000a0;to lactulose include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Galactosemia:</bold> Lactulose, due to its chemical composition, contains galactose and is contraindicated in patients requiring a galactose-free diet.<xref ref-type="bibr" rid="article-24004.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Diabetes:</bold> Although only a small fraction of lactulose undergoes systemic absorption, diabetes patients must use it cautiously due to the potential to cause hyperglycemia in diabetic individuals, as documented in a few studies.<xref ref-type="bibr" rid="article-24004.r20">[20]</xref><xref ref-type="bibr" rid="article-24004.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Older patients:</bold> Studies comparing the clinical efficacy and safety of other osmotic laxatives, such as sorbitol against lactulose, have concluded that in older patients, lactulose causes increased nausea as a side effect. Sorbitol is thus a safer and inexpensive drug to use in this population.<xref ref-type="bibr" rid="article-24004.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Pregnancy:</bold> Pregnancy is a stressor of hemodynamic physiology. Theoretically, via the drug's osmotic action, the prolonged use of lactulose may lead to electrolyte imbalances.<xref ref-type="bibr" rid="article-24004.r21">[21]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24004.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>From a pharmacokinetic standpoint, lactulose has negligible systemic absorption. However, like most laxatives,&#x000a0;lactulose tends to bring about large changes in the body's fluid and electrolyte status. This activity would require periodic electrolyte monitoring, especially in the older and critically ill population.<xref ref-type="bibr" rid="article-24004.r23">[23]</xref><xref ref-type="bibr" rid="article-24004.r24">[24]</xref></p>
        <p>The effects are particularly&#x000a0;profound regarding the sodium level, which commonly manifests as hypernatremia.<xref ref-type="bibr" rid="article-24004.r23">[23]</xref> In psychiatric patients on lithium therapy, there may be a risk for toxicity due to the decreased renal excretion of the drug due to volume depletion,&#x000a0; which would require careful drug monitoring.<xref ref-type="bibr" rid="article-24004.r25">[25]</xref></p>
      </sec>
      <sec id="article-24004.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Clinically, documentation on lactulose toxicity is lacking. Specific studies using rats inoculated with various concentrations of lactulose syrup ranging from 0.5% to 5% revealed no evidence of toxicity.<xref ref-type="bibr" rid="article-24004.r26">[26]</xref> However, there have been study results indicating the ability of lactulose to induce lithium toxicity in psychiatric patients. This effect is more broadly attributable to lactulose's ability to induce dehydration through its osmotic action, depletion of total body volume, and the resultant poor renal excretion of lithium.<xref ref-type="bibr" rid="article-24004.r25">[25]</xref> Although rare, documented allergic reactions to lactulose have been recorded in patients with milk allergies.<xref ref-type="bibr" rid="article-24004.r27">[27]</xref></p>
      </sec>
      <sec id="article-24004.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In the context of&#x000a0;hepatic encephalopathy management, multiple decision-making steps are involved to ensure the best patient care. These would range from the mode of administration of lactulose (either orally, rectally, or via a nasogastric tube) to monitoring the number of bowel movements to achieve the required frequency of 2&#x000a0;to 3 stools per day.<xref ref-type="bibr" rid="article-24004.r28">[28]</xref></p>
        <p>Communication between the physicians, advanced practice practitioners, pharmacists, and nursing staff, operating as an interprofessional team, is paramount to monitoring frequent changes in mental status and accurately measuring stool output. In certain situations, dose titration of the lactulose may also be required to prevent dehydration, diarrhea, and excoriation of the anal skin, requiring pharmaceutical intervention. Patients in the ICU requiring lactulose administered via a&#x000a0;nasogastric tube would need physical positioning designed to decrease the odds of aspiration.</p>
      </sec>
      <sec id="article-24004.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24004&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24004">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24004/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24004">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24004.s11">
        <title>References</title>
        <ref id="article-24004.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haemmerli</surname>
                <given-names>UP</given-names>
              </name>
              <name>
                <surname>Bircher</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Wrong idea, good results (the lactulose story).</article-title>
            <source>N Engl J Med</source>
            <year>1969</year>
            <month>Aug</month>
            <day>21</day>
            <volume>281</volume>
            <issue>8</issue>
            <fpage>441</fpage>
            <page-range>441-2</page-range>
            <pub-id pub-id-type="pmid">5797190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhiman</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Sawhney</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dilawari</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy.</article-title>
            <source>Dig Dis Sci</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>1549</fpage>
            <page-range>1549-52</page-range>
            <pub-id pub-id-type="pmid">11007104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wesselius-De Casparis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Braadbaart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bergh-Bohlken</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Mimica</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment of chronic constipation with lactulose syrup: results of a double-blind study.</article-title>
            <source>Gut</source>
            <year>1968</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-6</page-range>
            <pub-id pub-id-type="pmid">4867936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Portalatin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winstead</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Medical management of constipation.</article-title>
            <source>Clin Colon Rectal Surg</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-9</page-range>
            <pub-id pub-id-type="pmid">23449608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanBerge-Henegouwen</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Portincasa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Erpecum</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Effect of lactulose and fiber-rich diets on bile in relation to gallstone disease: an update.</article-title>
            <source>Scand J Gastroenterol Suppl</source>
            <year>1997</year>
            <volume>222</volume>
            <fpage>68</fpage>
            <page-range>68-71</page-range>
            <pub-id pub-id-type="pmid">9145452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Blanchard</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Lactulose as a novel template for anticancer drug development targeting galectins.</article-title>
            <source>Chem Biol Drug Des</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>1801</fpage>
            <page-range>1801-1808</page-range>
            <pub-id pub-id-type="pmid">29888844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elkington</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Lactulose.</article-title>
            <source>Gut</source>
            <year>1970</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>1043</fpage>
            <page-range>1043-8</page-range>
            <pub-id pub-id-type="pmid">4929274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dhiman</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Duseja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.</article-title>
            <source>Hepatology</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>549</fpage>
            <page-range>549-59</page-range>
            <pub-id pub-id-type="pmid">17326150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahimi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Singal</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Cuthbert</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rockey</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.</article-title>
            <source>JAMA Intern Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>174</volume>
            <issue>11</issue>
            <fpage>1727</fpage>
            <page-range>1727-33</page-range>
            <pub-id pub-id-type="pmid">25243839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aldridge</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Tranah</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Shawcross</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation.</article-title>
            <source>J Clin Exp Hepatol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>Suppl 1</issue>
            <fpage>S7</fpage>
            <page-range>S7-S20</page-range>
            <pub-id pub-id-type="pmid">26041962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uribe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campollo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ravelli</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Mundo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zapata</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garcia-Ramos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial.</article-title>
            <source>Hepatology</source>
            <year>1987</year>
            <season>Jul-Aug</season>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>639</fpage>
            <page-range>639-43</page-range>
            <pub-id pub-id-type="pmid">3301614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raza</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bhatti</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Akram</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of rectal lactulose administration with oral therapy on time to recovery from hepatic encephalopathy: a randomized study.</article-title>
            <source>Ann Saudi Med</source>
            <year>2004</year>
            <season>Sep-Oct</season>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>374</fpage>
            <page-range>374-7</page-range>
            <pub-id pub-id-type="pmid">15573853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mossalayi</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Dalloul</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bertho</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bismuth</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Blanc</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Debr&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Stage specific phosphoinositides turnover capacity of human intrathymic T cells following CD2-triggering.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>1990</year>
            <month>Apr</month>
            <day>30</day>
            <volume>168</volume>
            <issue>2</issue>
            <fpage>665</fpage>
            <page-range>665-71</page-range>
            <pub-id pub-id-type="pmid">1970727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Body</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal Diseases in Pregnancy: Nausea, Vomiting, Hyperemesis Gravidarum, Gastroesophageal Reflux Disease, Constipation, and Diarrhea.</article-title>
            <source>Gastroenterol Clin North Am</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>267</fpage>
            <page-range>267-83</page-range>
            <pub-id pub-id-type="pmid">27261898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomes</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Louren&#x000e7;o</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal diseases during pregnancy: what does the gastroenterologist need to know?</article-title>
            <source>Ann Gastroenterol</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>385</fpage>
            <page-range>385-394</page-range>
            <pub-id pub-id-type="pmid">29991883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jarzebicka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sieczkowska-Golub</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kierkus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Czubkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kowalczuk-Kryston</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pelc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lebensztejn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Korczowski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Socha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oracz</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>PEG 3350 Versus Lactulose for Treatment of Functional Constipation in Children: Randomized Study.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>68</volume>
            <issue>3</issue>
            <fpage>318</fpage>
            <page-range>318-324</page-range>
            <pub-id pub-id-type="pmid">30383579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabbers</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>DiLorenzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Faure</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Langendam</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Nurko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Staiano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vandenplas</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Benninga</surname>
                <given-names>MA</given-names>
              </name>
              <collab>European Society for Pediatric Gastroenterology, Hepatology, and Nutrition</collab>
              <collab>North American Society for Pediatric Gastroenterology</collab>
            </person-group>
            <article-title>Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-74</page-range>
            <pub-id pub-id-type="pmid">24345831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schuchmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.</article-title>
            <source>Eur J Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>434</fpage>
            <page-range>434-450</page-range>
            <pub-id pub-id-type="pmid">30444745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bae</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Long-term safety of PEG 4000 in children with chronic functional constipation: A biochemical perspective.</article-title>
            <source>Korean J Pediatr</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>53</volume>
            <issue>7</issue>
            <fpage>741</fpage>
            <page-range>741-4</page-range>
            <pub-id pub-id-type="pmid">21189949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirkman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Filippini</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Marked deterioration in glycemic control with change in brand of lactulose syrup.</article-title>
            <source>South Med J</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>492</fpage>
            <page-range>492-3</page-range>
            <pub-id pub-id-type="pmid">7716610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longo</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Canzoneri</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Robichaux</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal Conditions during Pregnancy.</article-title>
            <source>Clin Colon Rectal Surg</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>80</fpage>
            <page-range>80-9</page-range>
            <pub-id pub-id-type="pmid">21629625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lederle</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Mattox</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Aske</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose.</article-title>
            <source>Am J Med</source>
            <year>1990</year>
            <month>Nov</month>
            <volume>89</volume>
            <issue>5</issue>
            <fpage>597</fpage>
            <page-range>597-601</page-range>
            <pub-id pub-id-type="pmid">2122724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Fluid and electrolyte disturbances in critically ill patients.</article-title>
            <source>Electrolyte Blood Press</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>72</fpage>
            <page-range>72-81</page-range>
            <pub-id pub-id-type="pmid">21468200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Go</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Update on the management of constipation in the elderly: new treatment options.</article-title>
            <source>Clin Interv Aging</source>
            <year>2010</year>
            <month>Aug</month>
            <day>09</day>
            <volume>5</volume>
            <fpage>163</fpage>
            <page-range>163-71</page-range>
            <pub-id pub-id-type="pmid">20711435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bregman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fritz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Lactulose-associated lithium toxicity: a case series.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>742</fpage>
            <page-range>742-3</page-range>
            <pub-id pub-id-type="pmid">25133791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baskaran</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Mahadevamma</surname>
              </name>
              <name>
                <surname>Vishwanatha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lokesh</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Sub chronic toxicity studies of lactulose in rats.</article-title>
            <source>Indian J Exp Biol</source>
            <year>2001</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>441</fpage>
            <page-range>441-6</page-range>
            <pub-id pub-id-type="pmid">11510127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maiello</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Del Giudice</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Capristo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Decimo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Santaniello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Severe allergic reaction to lactulose in a child with milk allergy.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>107</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <pub-id pub-id-type="pmid">21704890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24004.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pantham</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mullen</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Practical Issues in the Management of Overt Hepatic Encephalopathy.</article-title>
            <source>Gastroenterol Hepatol (N Y)</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>659</fpage>
            <page-range>659-665</page-range>
            <pub-id pub-id-type="pmid">29230145</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
